All In Biotech

NDA 022370 · Cipher Pharms INC

Conzip

Tramadol Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 7, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

477

87 Phase 3, 25 recruiting

FAERS reports

38,170

34,489 serious, 7,659 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE CAPSULES WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE CAPSULES See full prescribing information for complete boxed warning. Tramadol Hydrochloride Extended-Release Capsules exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration are essential. Instruct patients to swallow Tramadol Hydrochloride Extended-Release Capsules intact, and not to split, chew, crush, or dissolve content of the capsules to...

What it is approved for

From the label in effect Jan 23, 2026.

Tramadol Hydrochloride Extended-Release Capsules are indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Tramadol Hydrochloride Extended-Release Capsules are an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Tramadol Hydrochloride Extended-Release Capsules, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) Tramadol Hydrochloride Extended-Release Capsules are not indicated as an as-needed (prn) analgesic. ( 1 ) Limitation of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including Tramadol Hydrochloride Extended-Release Capsules, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Tramadol Hydrochloride Extended-Release Capsules are not indicated as an as-needed (prn) analgesic.

Mechanism: Tramadol Hydrochloride Extended-Release Capsules contain tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to mu-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity of tramadol is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to mu-opioid receptors. In animal models,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 7, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LabelREMSLetter
4 products under this application
  • CONZIP · TRAMADOL HYDROCHLORIDE 150MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
  • CONZIP · TRAMADOL HYDROCHLORIDE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • CONZIP · TRAMADOL HYDROCHLORIDE 300MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • CONZIP · TRAMADOL HYDROCHLORIDE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tramadol" as an intervention, any sponsor and status, largest first.

All 477 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dependence7,835
  • overdose3,935
  • vomiting3,558
  • pain3,208
  • nausea3,009
  • drug ineffective2,827
  • dyspnoea2,557
  • off label use2,552
  • headache2,497
  • fatigue2,488
  • drug hypersensitivity2,376
  • drug dependence2,206

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004115
2005129
200694
200750
2008124
2009230
2010564
2011492
2012938
2013670
2014635
2015991
20161,044
20171,556
20181,826
20192,310
20202,130
20212,976
20222,925
20239,952
20243,702
20252,810
20261,905

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Conzip (Tramadol HCl)

2024 spending

$41K

Beneficiaries

11

60 claims

Per beneficiary

$3,755

$15.42 per unit

View as table
YearSpending
2020$120,822
2021$103,826
2022$49,540
2023$42,303
2024$41,304

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,874 on PubMed

Sponsor: Cipher Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.